Industries > Pharma > Amyotrophic Lateral Sclerosis Treatment Market Report to 2031
Amyotrophic Lateral Sclerosis Treatment Market Report to 2031
Forecasts by Treatment Type (Chemotherapy and Stem Cell Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS COVID-19 Recovery Scenarios
Amyotrophic Lateral Sclerosis Treatment Market – our new study reveals trends, R&D progress, and predicted revenues
Where is the Amyotrophic Lateral Sclerosis Treatment market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenue streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
500+ page report provides 600+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and future market prospects. Our new study lets you assess forecasted sales at the overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Amyotrophic Lateral Sclerosis Treatment Market. See how to exploit opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles, and commercial developments.
Discover sales predictions for the world market and submarkets
Amyotrophic Lateral Sclerosis Treatment Market: By Treatment Type
• Chemotherapy
• Stem Cell Therapy
Amyotrophic Lateral Sclerosis Treatment Market: By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Amyotrophic Lateral Sclerosis Treatment Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Amyotrophic Lateral Sclerosis Treatment Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Amyotrophic Lateral Sclerosis Treatment Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Amyotrophic Lateral Sclerosis Treatment Market, with forecasts for Treatment Type, and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Amyotrophic Lateral Sclerosis Treatment market in North America, Europe, Asia-Pacific, and Rest of the World. Also forecasted are the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Amyotrophic Lateral Sclerosis Treatment Market. Some of the companies profiled in this report include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F.Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Amyotrophic Lateral Sclerosis Treatment Market Report to 2031: Forecasts by Treatment Type (Chemotherapy and Stem Cell Therapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Amyotrophic Lateral Sclerosis Treatment Market
2.1. Amyotrophic Lateral Sclerosis Treatment Market Definition
2.2. Treatment Type Submarkets Definitions
2.3. Distribution Channel Submarkets Definitions
3. Amyotrophic Lateral Sclerosis Treatment Market Overview
3.1. Global Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Region
3.2. Global Amyotrophic Lateral Sclerosis Treatment Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Prevalence of ALS
3.3.1.2. The inclination towards the sedentary lifestyle
3.3.1.3. The increasing geriatric population substantiates market growth, creating a demand for symptomatic and targeted treatment options
3.3.2. Market Restraints/Challenges
3.3.2.1. High prices of advanced Treatment
3.3.2.2. Awareness about Amyotrophic Lateral Sclerosis's disease remains limited in developing countries
3.3.2.3. Stringent Regulations
3.3.2.4. Threat of Patent Expiration
3.3.3. Opportunities
3.3.3.1. Rising R&D for treatment of ALS disease
3.3.4. Global Amyotrophic Lateral Sclerosis Treatment Market: Trends
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 by Treatment Type (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Chemotherapy
4.1.2. Stem Cell Therapy
5. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Hospital Pharmacy
5.1.2. Retail Pharmacy
5.1.3. Online Pharmacies
6. North America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
6.3. North America Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
6.4. U.S. Amyotrophic Lateral Sclerosis Treatment Market
6.5. Canada Amyotrophic Lateral Sclerosis Treatment Market
7. Europe Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
7.3. Europe Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
7.4. UK Amyotrophic Lateral Sclerosis Treatment Market
7.5. Germany Amyotrophic Lateral Sclerosis Treatment Market
7.6. France Amyotrophic Lateral Sclerosis Treatment Market
7.7. Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market
8. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
8.3. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
8.4. China Amyotrophic Lateral Sclerosis Treatment Market
8.5. India Amyotrophic Lateral Sclerosis Treatment Market
8.6. Japan Amyotrophic Lateral Sclerosis Treatment Market
8.7. Rest of Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market
9. Latin America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
9.3. Latin America Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
9.3.1. Brazil Amyotrophic Lateral Sclerosis Treatment Market
9.3.2. Mexico Amyotrophic Lateral Sclerosis Treatment Market
9.3.3. Rest of Latin America Amyotrophic Lateral Sclerosis Treatment Market
10. MEA Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
10.3. MEA Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
10.4. GCC Amyotrophic Lateral Sclerosis Treatment Market
10.5. South Africa Amyotrophic Lateral Sclerosis Treatment Market
10.6. Rest of MEA Amyotrophic Lateral Sclerosis Treatment Market
11. Companies in the Amyotrophic Lateral Sclerosis Treatment Market
11.1. Mitsubishi Tanabe Pharma Corporation
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.3. Financial Performance (2015-2019)
11.1.3.1. Net Revenue
11.1.3.2. Gross Profit
11.1.3.3. Geographical Revenue, 2019
11.1.4. Product Offerings
11.1.5. Recent Initiatives (2017-2019)
11.2. Otsuka Pharmaceutical Co., Ltd.
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2019)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.3.3. Geographical Revenue, 2019
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2019)
11.3. BrainStorm Therapeutics
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2019)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.3.3. Geographical Revenue, 2019
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2019)
11.4. Biogen Inc.
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2019)
11.4.3.1. Net Revenue
11.4.3.2. Gross Profit
11.4.3.3. Geographical Revenue, 2019
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2019)
11.5. Corestem
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2019)
11.5.3.1. Net Revenue
11.5.3.2. Gross Profit
11.5.3.3. Geographical Revenue, 2019
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2019)
11.6. AB Science
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2019)
11.6.3.1. Net Revenue
11.6.3.2. Gross Profit
11.6.3.3. Geographical Revenue, 2019
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2019)
11.7. F.Hoffmann-La Roche AG
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2019)
11.7.3.1. Net Revenue
11.7.3.2. Gross Profit
11.7.3.3. Geographical Revenue, 2019
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2019)
11.8. Biohaven Pharmaceutical
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2019)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.3.3. Geographical Revenue, 2019
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2019)
11.9. Sun Pharmaceutical
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2019)
11.9.3.1. Net Revenue
11.9.3.2. Gross Profit
11.9.3.3. Geographical Revenue, 2019
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2019)
11.10. Ionis Pharmaceuticals, Inc.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2019)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.3.3. Geographical Revenue, 2019
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2019)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Amyotrophic Lateral Sclerosis Treatment Market Drivers & Restraints 2020
Table 7 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 8 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 18 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 19 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 20 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 21 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 22 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 23 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 24 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 25 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 26 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 27 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 28 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 29 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 30 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 31 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 32 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 33 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 34 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 35 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 36 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 37 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 38 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 39 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 40 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 41 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 42 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 43 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 44 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 45 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 46 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 47 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 48 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 49 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 50 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 51 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 52 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 53 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 54 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 55 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 56 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 57 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 58 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 59 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 60 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 61 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 62 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 63 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 64 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 65 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 66 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 67 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 68 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 69 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 70 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 71 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 72 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 73 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 74 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 75 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 76 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 77 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 78 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 79 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 80 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 81 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 94 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 95 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 100 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 111 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 115 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 171 Leading 10 Amyotrophic Lateral Sclerosis Treatment Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 172 Mitsubishi Tanabe Pharma Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 173 Mitsubishi Tanabe Pharma Corporation Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 174 Mitsubishi Tanabe Pharma Corporation Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 175 Otsuka Pharmaceutical Co., Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 176 Otsuka Pharmaceutical Co., Ltd. Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 177 Otsuka Pharmaceutical Co., Ltd. Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 178 BrainStorm Therapeutics Profile 2019 (CEO, HQ, Founded, Website)
Table 179 BrainStorm Therapeutics Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2017-2019 (Date, Contract Treatment Type, Details)
Table 180 BrainStorm Therapeutics Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 181 Biogen Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 182 Biogen Inc. Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 183 Biogen Inc. Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 184 Corestem Profile 2019 (CEO, HQ, Founded, Website)
Table 185 Corestem Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 186 Corestem Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 187 AB Science Profile 2019 (CEO, HQ, Founded, Website)
Table 188 AB Science Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 189 AB Science Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 190 F.Hoffmann-La Roche AG Profile 2019 (CEO, HQ, Founded, Website)
Table 191 F.Hoffmann-La Roche AG Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 192 F.Hoffmann-La Roche AG Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 193 Biohaven Pharmaceutical Profile 2019 (CEO, HQ, Founded, Website)
Table 194 Biohaven Pharmaceutical Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 195 Biohaven Pharmaceutical Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 196 Sun Pharmaceutical Profile 2019 (CEO, HQ, Founded, Website)
Table 197 Sun Pharmaceutical Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 198 Sun Pharmaceutical Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 199 Ionis Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 200 Ionis Pharmaceuticals, Inc. Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 201 Ionis Pharmaceuticals, Inc. Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 202 Other Companies Involved in the Amyotrophic Lateral Sclerosis Treatment Market 2020 (Company, Location)
LIST OF FIGURES
Figure 1 Amyotrophic Lateral Sclerosis Treatment Market by Treatment Type Overview
Figure 2 Amyotrophic Lateral Sclerosis Treatment Market by Distribution Channel Overview
Figure 3 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 4 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 5 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 6 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 7 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 8 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 9 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 10 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 11 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 12 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 13 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 14 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 15 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 16 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 17 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 18 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 43 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 44 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 45 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 46 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 47 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 48 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 49 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 50 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 51 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 52 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 53 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 54 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 55 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 56 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 57 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 58 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 59 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 60 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 61 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 62 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 63 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 64 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 65 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 66 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 67 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 68 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 69 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 70 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 71 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 72 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 73 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 74 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 75 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 76 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 77 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 78 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 79 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 80 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 81 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 82 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 83 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 84 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 85 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 86 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 87 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 88 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 89 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 90 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 91 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 92 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 93 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 94 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 95 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 96 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 97 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 98 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 99 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 100 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 101 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 102 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 103 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 104 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 105 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 106 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 107 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 108 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 109 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 110 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 111 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 112 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 113 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 114 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 115 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 116 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 117 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 118 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 119 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 120 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 121 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 122 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 123 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 124 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 125 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 126 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 127 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 128 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 129 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 130 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 131 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 132 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Amyotrophic Lateral Sclerosis Treatment Market
2.1. Amyotrophic Lateral Sclerosis Treatment Market Definition
2.2. Treatment Type Submarkets Definitions
2.3. Distribution Channel Submarkets Definitions
3. Amyotrophic Lateral Sclerosis Treatment Market Overview
3.1. Global Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Region
3.2. Global Amyotrophic Lateral Sclerosis Treatment Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing Prevalence of ALS
3.3.1.2. The inclination towards the sedentary lifestyle
3.3.1.3. The increasing geriatric population substantiates market growth, creating a demand for symptomatic and targeted treatment options
3.3.2. Market Restraints/Challenges
3.3.2.1. High prices of advanced Treatment
3.3.2.2. Awareness about Amyotrophic Lateral Sclerosis's disease remains limited in developing countries
3.3.2.3. Stringent Regulations
3.3.2.4. Threat of Patent Expiration
3.3.3. Opportunities
3.3.3.1. Rising R&D for treatment of ALS disease
3.3.4. Global Amyotrophic Lateral Sclerosis Treatment Market: Trends
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.2. Weaknesses
3.3.5.3. Opportunities
3.3.5.4. Threats
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. The threat of New Entry
4. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 by Treatment Type (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Chemotherapy
4.1.2. Stem Cell Therapy
5. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 by Distribution Channel (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Hospital Pharmacy
5.1.2. Retail Pharmacy
5.1.3. Online Pharmacies
6. North America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
6.1. Market Overview
6.2. North America Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
6.3. North America Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
6.4. U.S. Amyotrophic Lateral Sclerosis Treatment Market
6.5. Canada Amyotrophic Lateral Sclerosis Treatment Market
7. Europe Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. Europe Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
7.3. Europe Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
7.4. UK Amyotrophic Lateral Sclerosis Treatment Market
7.5. Germany Amyotrophic Lateral Sclerosis Treatment Market
7.6. France Amyotrophic Lateral Sclerosis Treatment Market
7.7. Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market
8. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
8.3. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
8.4. China Amyotrophic Lateral Sclerosis Treatment Market
8.5. India Amyotrophic Lateral Sclerosis Treatment Market
8.6. Japan Amyotrophic Lateral Sclerosis Treatment Market
8.7. Rest of Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market
9. Latin America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Latin America Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
9.3. Latin America Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
9.3.1. Brazil Amyotrophic Lateral Sclerosis Treatment Market
9.3.2. Mexico Amyotrophic Lateral Sclerosis Treatment Market
9.3.3. Rest of Latin America Amyotrophic Lateral Sclerosis Treatment Market
10. MEA Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W, and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. MEA Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Treatment Type
10.3. MEA Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast by Distribution Channel
10.4. GCC Amyotrophic Lateral Sclerosis Treatment Market
10.5. South Africa Amyotrophic Lateral Sclerosis Treatment Market
10.6. Rest of MEA Amyotrophic Lateral Sclerosis Treatment Market
11. Companies in the Amyotrophic Lateral Sclerosis Treatment Market
11.1. Mitsubishi Tanabe Pharma Corporation
11.1.1. Company Snapshot
11.1.2. Company Overview
11.1.3. Financial Performance (2015-2019)
11.1.3.1. Net Revenue
11.1.3.2. Gross Profit
11.1.3.3. Geographical Revenue, 2019
11.1.4. Product Offerings
11.1.5. Recent Initiatives (2017-2019)
11.2. Otsuka Pharmaceutical Co., Ltd.
11.2.1. Company Snapshot
11.2.2. Company Overview
11.2.3. Financial Performance (2015-2019)
11.2.3.1. Net Revenue
11.2.3.2. Gross Profit
11.2.3.3. Geographical Revenue, 2019
11.2.4. Product Offerings
11.2.5. Recent Initiatives (2017-2019)
11.3. BrainStorm Therapeutics
11.3.1. Company Snapshot
11.3.2. Company Overview
11.3.3. Financial Performance (2015-2019)
11.3.3.1. Net Revenue
11.3.3.2. Gross Profit
11.3.3.3. Geographical Revenue, 2019
11.3.4. Product Offerings
11.3.5. Recent Initiatives (2017-2019)
11.4. Biogen Inc.
11.4.1. Company Snapshot
11.4.2. Company Overview
11.4.3. Financial Performance (2015-2019)
11.4.3.1. Net Revenue
11.4.3.2. Gross Profit
11.4.3.3. Geographical Revenue, 2019
11.4.4. Product Offerings
11.4.5. Recent Initiatives (2017-2019)
11.5. Corestem
11.5.1. Company Snapshot
11.5.2. Company Overview
11.5.3. Financial Performance (2015-2019)
11.5.3.1. Net Revenue
11.5.3.2. Gross Profit
11.5.3.3. Geographical Revenue, 2019
11.5.4. Product Offerings
11.5.5. Recent Initiatives (2017-2019)
11.6. AB Science
11.6.1. Company Snapshot
11.6.2. Company Overview
11.6.3. Financial Performance (2015-2019)
11.6.3.1. Net Revenue
11.6.3.2. Gross Profit
11.6.3.3. Geographical Revenue, 2019
11.6.4. Product Offerings
11.6.5. Recent Initiatives (2017-2019)
11.7. F.Hoffmann-La Roche AG
11.7.1. Company Snapshot
11.7.2. Company Overview
11.7.3. Financial Performance (2015-2019)
11.7.3.1. Net Revenue
11.7.3.2. Gross Profit
11.7.3.3. Geographical Revenue, 2019
11.7.4. Product Offerings
11.7.5. Recent Initiatives (2017-2019)
11.8. Biohaven Pharmaceutical
11.8.1. Company Snapshot
11.8.2. Company Overview
11.8.3. Financial Performance (2015-2019)
11.8.3.1. Net Revenue
11.8.3.2. Gross Profit
11.8.3.3. Geographical Revenue, 2019
11.8.4. Product Offerings
11.8.5. Recent Initiatives (2017-2019)
11.9. Sun Pharmaceutical
11.9.1. Company Snapshot
11.9.2. Company Overview
11.9.3. Financial Performance (2015-2019)
11.9.3.1. Net Revenue
11.9.3.2. Gross Profit
11.9.3.3. Geographical Revenue, 2019
11.9.4. Product Offerings
11.9.5. Recent Initiatives (2017-2019)
11.10. Ionis Pharmaceuticals, Inc.
11.10.1. Company Snapshot
11.10.2. Company Overview
11.10.3. Financial Performance (2015-2019)
11.10.3.1. Net Revenue
11.10.3.2. Gross Profit
11.10.3.3. Geographical Revenue, 2019
11.10.4. Product Offerings
11.10.5. Recent Initiatives (2017-2019)
11.11. Other Notable Players
12. Conclusion
13. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6 Amyotrophic Lateral Sclerosis Treatment Market Drivers & Restraints 2020
Table 7 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 8 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 9 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 10 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 11 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 12 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 18 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 19 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 20 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 21 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 22 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 23 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 24 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 25 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 26 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 27 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 28 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 29 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 30 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 31 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 32 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 33 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 34 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 35 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 36 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 37 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 38 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 39 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 40 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 41 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 42 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 43 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 44 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 45 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 46 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 47 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 48 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 49 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 50 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 51 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 52 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 53 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 54 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 55 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 56 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 57 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 58 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 59 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 60 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 61 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 62 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 63 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 64 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 65 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 66 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 67 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 68 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 69 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 70 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 71 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 72 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 73 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 74 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 75 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 76 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 77 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 78 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 79 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 80 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 81 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 82 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 83 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 84 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 85 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 86 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 87 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 88 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 89 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 90 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 91 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 92 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 93 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 94 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 95 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 96 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 97 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 98 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 99 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 100 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 101 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 102 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 103 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 104 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 105 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 106 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 107 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 108 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 109 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 110 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 111 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 112 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 113 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 114 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 115 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 116 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 117 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 118 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 119 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 120 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 121 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 122 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 123 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 124 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 125 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 126 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 127 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 128 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 129 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 130 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 131 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 132 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 133 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 134 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 135 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 136 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 137 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 138 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 139 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 140 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 141 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 142 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 143 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 144 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 145 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 146 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 147 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 148 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 149 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 150 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 151 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 152 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 153 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 154 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 155 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 156 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 157 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 158 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 159 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 160 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 161 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 162 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 163 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 164 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 165 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 166 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 167 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 168 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 169 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 170 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 171 Leading 10 Amyotrophic Lateral Sclerosis Treatment Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 172 Mitsubishi Tanabe Pharma Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 173 Mitsubishi Tanabe Pharma Corporation Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 174 Mitsubishi Tanabe Pharma Corporation Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 175 Otsuka Pharmaceutical Co., Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 176 Otsuka Pharmaceutical Co., Ltd. Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2019 (Date, Contract Treatment Type, Details)
Table 177 Otsuka Pharmaceutical Co., Ltd. Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 178 BrainStorm Therapeutics Profile 2019 (CEO, HQ, Founded, Website)
Table 179 BrainStorm Therapeutics Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2017-2019 (Date, Contract Treatment Type, Details)
Table 180 BrainStorm Therapeutics Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 181 Biogen Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 182 Biogen Inc. Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 183 Biogen Inc. Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 184 Corestem Profile 2019 (CEO, HQ, Founded, Website)
Table 185 Corestem Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 186 Corestem Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 187 AB Science Profile 2019 (CEO, HQ, Founded, Website)
Table 188 AB Science Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 189 AB Science Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 190 F.Hoffmann-La Roche AG Profile 2019 (CEO, HQ, Founded, Website)
Table 191 F.Hoffmann-La Roche AG Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 192 F.Hoffmann-La Roche AG Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 193 Biohaven Pharmaceutical Profile 2019 (CEO, HQ, Founded, Website)
Table 194 Biohaven Pharmaceutical Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 195 Biohaven Pharmaceutical Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 196 Sun Pharmaceutical Profile 2019 (CEO, HQ, Founded, Website)
Table 197 Sun Pharmaceutical Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 198 Sun Pharmaceutical Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 199 Ionis Pharmaceuticals, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 200 Ionis Pharmaceuticals, Inc. Amyotrophic Lateral Sclerosis Treatment Selected Recent Contracts 2015-2019 (Date, Contract Treatment Type, Details)
Table 201 Ionis Pharmaceuticals, Inc. Amyotrophic Lateral Sclerosis Treatment Product Offering (Segment, Product Offerings)
Table 202 Other Companies Involved in the Amyotrophic Lateral Sclerosis Treatment Market 2020 (Company, Location)
LIST OF FIGURES
Figure 1 Amyotrophic Lateral Sclerosis Treatment Market by Treatment Type Overview
Figure 2 Amyotrophic Lateral Sclerosis Treatment Market by Distribution Channel Overview
Figure 3 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 4 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 5 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 6 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 7 Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 8 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 9 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 10 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 11 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 12 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 13 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 14 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 15 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 16 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 17 Chemotherapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 18 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21 Stem Cell Therapy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26 Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31 Hospital Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36 Retail Pharmacy Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41 Online Pharmacies Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 43 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 44 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 45 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 46 Regional Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 47 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 48 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 49 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 50 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 51 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 52 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 53 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 54 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 55 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 56 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 57 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 58 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 59 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 60 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 61 North America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 62 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 63 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 64 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 65 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 66 US Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 67 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 68 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 69 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 70 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 71 Canada Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 72 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 73 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 74 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 75 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 76 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 77 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 78 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 79 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 80 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 81 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 82 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 83 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 84 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 85 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 86 Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 87 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 88 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 89 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 90 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 91 UK Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 92 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 93 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 94 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 95 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 96 Germany Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 97 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 98 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 99 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 100 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 101 France Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 102 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 103 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 104 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 105 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 106 Rest of Europe Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 107 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 108 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 109 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 110 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 111 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 112 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 113 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 114 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 115 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 116 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 117 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 118 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 119 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 120 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 121 Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 122 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 123 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 124 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 125 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 126 China Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 127 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 128 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 129 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 130 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 131 India Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 132 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 133 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 134 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 135 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 136 Japan Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 137 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 138 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 139 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 140 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 141 RoAPAC Amyotrophic Lateral Sclerosis Treatment Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 142 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 143 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 144 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 145 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 146 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 147 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 148 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 149 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 150 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 151 Middle East Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 152 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 153 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 154 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 155 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 156 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 157 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161 Latin America Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Treatment Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171 Africa Amyotrophic Lateral Sclerosis Treatment Market Forecast by Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Companies Profiled in the Report
1. Mitsubishi Tanabe Pharma Corporation
2. Otsuka Pharmaceutical Co., Ltd.
3. BrainStorm Therapeutics
4. Biogen Inc.
5. Corestem
6. AB Science
7. F.Hoffmann-La Roche AG
8. Biohaven Pharmaceutical
9. Sun Pharmaceutical
10. Ionis Pharmaceuticals, Inc.
List of Companies Mentioned in the Report:
1. Shionogi & Co.
2. Shanghai Fosun Pharmaceutical
3. Stada Arzneimittel
4. Lundbeck
5. Zhejiang International
6. Lupin
7. Taisho Pharmaceutical
8. Tasly Pharmaceutical
9. Ipsen
10. Sino Biopharmaceutical
11. Ono Pharmaceutical
12. Aurobindo
13. Cipla
14. Johnson & Johnson
15. Roche
16. Novartis
17. Sanofi
18. Bayer
19. Merck & Co. (MSD)
20. Eli Lilly
21. Astrazeneca
22. Teva
23. CR Pharmaceutical
24. Bristol-Myers Squibb
25. Merck (KGaA)
26. Novo Nordisk
27. Takeda
28. Allergan
29. Astellas Pharma
30. Mylan
31. Otsuka
32. Daiichi Sankyo
33. Valeant Pharmaceuticals
34. UCB
35. Zoetis
36. Eisai
37. Chugai Pharmaceutical
38. Perrigo
39. Sun Pharmaceutical
40. Mitsubishi Tanabe Pharma
41. Sichuan Languang Development
42. Sumitomo Dainippon Pharma
43. Yunnan Baiyao
44. Aspen Pharmacare
45. Endo
46. Kangmei Pharmaceutical
47. Galenica
48. Guangzhou Baiyunshan Pharmaceutical
49. Kyowa Hakko Kirin
50. Mallinckrod
List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care
1. Mitsubishi Tanabe Pharma Corporation
2. Otsuka Pharmaceutical Co., Ltd.
3. BrainStorm Therapeutics
4. Biogen Inc.
5. Corestem
6. AB Science
7. F.Hoffmann-La Roche AG
8. Biohaven Pharmaceutical
9. Sun Pharmaceutical
10. Ionis Pharmaceuticals, Inc.
List of Companies Mentioned in the Report:
1. Shionogi & Co.
2. Shanghai Fosun Pharmaceutical
3. Stada Arzneimittel
4. Lundbeck
5. Zhejiang International
6. Lupin
7. Taisho Pharmaceutical
8. Tasly Pharmaceutical
9. Ipsen
10. Sino Biopharmaceutical
11. Ono Pharmaceutical
12. Aurobindo
13. Cipla
14. Johnson & Johnson
15. Roche
16. Novartis
17. Sanofi
18. Bayer
19. Merck & Co. (MSD)
20. Eli Lilly
21. Astrazeneca
22. Teva
23. CR Pharmaceutical
24. Bristol-Myers Squibb
25. Merck (KGaA)
26. Novo Nordisk
27. Takeda
28. Allergan
29. Astellas Pharma
30. Mylan
31. Otsuka
32. Daiichi Sankyo
33. Valeant Pharmaceuticals
34. UCB
35. Zoetis
36. Eisai
37. Chugai Pharmaceutical
38. Perrigo
39. Sun Pharmaceutical
40. Mitsubishi Tanabe Pharma
41. Sichuan Languang Development
42. Sumitomo Dainippon Pharma
43. Yunnan Baiyao
44. Aspen Pharmacare
45. Endo
46. Kangmei Pharmaceutical
47. Galenica
48. Guangzhou Baiyunshan Pharmaceutical
49. Kyowa Hakko Kirin
50. Mallinckrod
List of Organizations Mentioned in the Report:
1. European Commission
2. European Medicines Agency
3. Food and Drug Administration
4. Medicines and Healthcare Regulatory Agency
5. Ministry of Industry and Information technology
6. National Institute of Health
7. World Health Organisation (WHO)
8. Centers for Disease Control and Prevention
9. National Academy of Medicine
10. Agency for Healthcare Research and Quality
11. National Accreditation Board for Hospitals & Healthcare Providers
12. National Institute for Health Research
13. Chinese Food and Drug Administration
14. Care Quality Commission
15. British Medical Association
16. United States Department of Health and Human Services
17. Healthcare Information and Management Systems Society
18. Patient safety organization
19. NHS Digital
20. Australian Commission On Safety And Quality In Health Care
Download sample pages
Complete the form below to download your free sample pages for Amyotrophic Lateral Sclerosis Treatment Market Report to 2031Download sample pages
Complete the form below to download your free sample pages for Amyotrophic Lateral Sclerosis Treatment Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Latest Pharma news
Pharmaceutical Contract Manufacturing Market
The global Pharmaceutical Contract Manufacturing market is projected to grow at a CAGR of 11.5% by 2034
30 July 2024
Retinal Gene Therapy Market
The global Retinal Gene Therapy market is projected to grow at a CAGR of 9.6% by 2034
26 July 2024
HIV Drugs and Injectables Market
The global HIV Drugs & Injectables market is projected to grow at a CAGR of 4.6 % by 2034
24 July 2024
Digital Twin Technology in Pharmaceutical Manufacturing Market
The global Digital Twin Technology in Pharmaceutical Manufacturing market is projected to grow at a CAGR of 31.3% by 2034
23 July 2024
